Everence Capital Management’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-8,940
| Closed | -$235 | – | 799 |
|
|
2024
Q2 | $235 | Hold |
8,940
| – | – | 0.02% | 627 |
|
|
2024
Q1 | $261 | Hold |
8,940
| – | – | 0.02% | 614 |
|
|
2023
Q4 | $302K | Hold |
8,940
| – | – | 0.02% | 561 |
|
|
2023
Q3 | $274 | Buy |
8,940
+2,830
| +46% | +$87 | 0.02% | 574 |
|
|
2023
Q2 | $232K | Hold |
6,110
| – | – | 0.02% | 602 |
|
|
2023
Q1 | $249 | Hold |
6,110
| – | – | 0.02% | 607 |
|
|
2022
Q4 | $236 | Hold |
6,110
| – | – | 0.02% | 627 |
|
|
2022
Q3 | $325K | Buy |
6,110
+2,080
| +52% | +$111K | 0.03% | 486 |
|
|
2022
Q2 | $235K | Hold |
4,030
| – | – | 0.02% | 592 |
|
|
2022
Q1 | $308K | Buy |
+4,030
| New | +$308K | 0.02% | 550 |
|
|
2021
Q3 | – | Sell |
-4,700
| Closed | -$285K | – | 757 |
|
|
2021
Q2 | $285K | Hold |
4,700
| – | – | 0.02% | 580 |
|
|
2021
Q1 | $329K | Buy |
+4,700
| New | +$329K | 0.03% | 519 |
|
|
2020
Q3 | – | Sell |
-6,900
| Closed | -$303K | – | 728 |
|
|
2020
Q2 | $303K | Hold |
6,900
| – | – | 0.04% | 453 |
|
|
2020
Q1 | $231K | Hold |
6,900
| – | – | 0.03% | 467 |
|
|
2019
Q4 | $313K | Buy |
+6,900
| New | +$313K | 0.05% | 469 |
|